Trademarkia Logo

Canada

C$
CTX213
FORMALIZED

on 15 Jan 2025

Last Applicant/ Owned by

CRISPR Therapeutics AG

Baarerstrasse 14ZUG V8, 6300

CH

Serial Number

2374428 filed on 15th Jan 2025

Correspondent Address

SMART & BIGGAR LP

SUITE 1000, 55 METCALFE STREETP.O. BOX 2999, STATION DOTTAWA

ONTARIO

CA

K1P5Y6

CTX213

Trademark usage description

cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regul Read More

Classification Information


Class [005]
Cells for medical or clinical use in the field of stem cell therapy for the treatment of diabetes; gene therapy products, namely, gene transfer, regulation, modulation and delivery pharmaceuticals for the treatment of diabetes; pharmaceutical and biopharmaceutical agents for the treatment of diabetes


Classification kind code

12

Class [042]
Gene editing, namely, pharmaceutical research and development in the field of stem cell therapy for the treatment of diabetes; Gene editing, namely, medical and scientific research for the treatment of genetic diseases and disorders in the field of stem cell therapy for the treatment of diabetes


Classification kind code

12

Mark Details


Serial Number

2374428

Mark Type

Trademark

Legal History


Action TakenStatus
Submitted for opposition 287
on 30th Jan 2025
Pre-Assessment Letter Sent
Submitted for opposition 30
on 15th Jan 2025
Filed
Submitted for opposition 1
on 15th Jan 2025
Created
Submitted for opposition 31
on 15th Jan 2025
Formalized